These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 38461065)
1. The complement system in the pathogenesis and progression of kidney diseases: What doesn't kill you makes you older. Stea ED; D'Ettorre G; Mitrotti A; Gesualdo L Eur J Intern Med; 2024 Jun; 124():22-31. PubMed ID: 38461065 [TBL] [Abstract][Full Text] [Related]
3. Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015. Noris M; Remuzzi G Am J Kidney Dis; 2015 Aug; 66(2):359-75. PubMed ID: 26032627 [No Abstract] [Full Text] [Related]
4. Complement Inhibitors in Clinical Trials for Glomerular Diseases. Zipfel PF; Wiech T; Rudnick R; Afonso S; Person F; Skerka C Front Immunol; 2019; 10():2166. PubMed ID: 31611870 [TBL] [Abstract][Full Text] [Related]
5. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Goodship TH; Cook HT; Fakhouri F; Fervenza FC; Frémeaux-Bacchi V; Kavanagh D; Nester CM; Noris M; Pickering MC; Rodríguez de Córdoba S; Roumenina LT; Sethi S; Smith RJ; Kidney Int; 2017 Mar; 91(3):539-551. PubMed ID: 27989322 [TBL] [Abstract][Full Text] [Related]
6. Molecules Great and Small: The Complement System. Mathern DR; Heeger PS Clin J Am Soc Nephrol; 2015 Sep; 10(9):1636-50. PubMed ID: 25568220 [TBL] [Abstract][Full Text] [Related]
7. Targeting the complement cascade: novel treatments coming down the pike. Thurman JM; Le Quintrec M Kidney Int; 2016 Oct; 90(4):746-52. PubMed ID: 27325183 [TBL] [Abstract][Full Text] [Related]
8. [The complement system-a "hot topic" not only for kidney diseases]. Amann K; Daniel C; Büttner-Herold M Pathologe; 2020 May; 41(3):238-247. PubMed ID: 32240352 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Anliker-Ort M; Dingemanse J; van den Anker J; Kaufmann P Front Immunol; 2020; 11():599417. PubMed ID: 33362783 [TBL] [Abstract][Full Text] [Related]
15. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. Asif A; Nayer A; Haas CS J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226 [TBL] [Abstract][Full Text] [Related]
16. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Antonucci L; Thurman JM; Vivarelli M Pediatr Nephrol; 2024 May; 39(5):1387-1404. PubMed ID: 37733095 [TBL] [Abstract][Full Text] [Related]
17. A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug intervention. Zewde N; Morikis D PLoS One; 2018; 13(6):e0198644. PubMed ID: 29874282 [TBL] [Abstract][Full Text] [Related]